David Hallal has sold stock and made no open-market buys since Feb 2016

David Hallal is a 30-year veteran in the biopharmaceutical industry with extensive expertise in early-stage company building and operating large multinational biotech companies( He serves as Chairman and Chief Executive Officer of Scholar Rock Holding Corp (NASDAQ: SRRK)( a position he has held while also serving as Executive Chairman of ElevateBio, which he co-founded, and as Chairman of iTeos Therapeutics and Kalaris Therapeutics(

Hallal's career includes more than a decade at Alexion Pharmaceuticals, where he served as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer( During his tenure, he played a central role in transforming Alexion from a pre-commercial stage company in 2006 to greater than $3 billion in annual revenues by 2016( As CEO, he transitioned the company from a single product to a multi-product enterprise and built the company's commercial infrastructure and 50-country operating platform, successfully launching Soliris for ultra-rare diseases and achieving the most successful commercialization of an ultra-orphan drug in the biotechnology industry( Hallal holds a B.A. in Psychology from the University of New Hampshire(

Written by Perplexity from public sources.